Egalet (NSDQ:EGLT) has partnered with a division of Valeant Pharmaceuticals (NYSE:VRX), OraPharma, to co-promote its pain-relief nasal spray to dentists and oral surgeons in the U.S.
Sprix nasal spray is a nonsteroidal anti-inflammatory drug designed for the short-term management of moderate to moderately-severe pain.
Financial terms of the two-year deal were not disclosed.
“Given the need for additional non-narcotic analgesics in the dental space, we believe Sprix nasal spray offers an attractive product profile that can complement the OraPharma line of oral health products,” chief operating officer Mark Strobeck said in prepared remarks. “This partnership, which expands our commercial reach, represents one aspect of our business development strategy which also includes acquisition of late-stage or approved assets and out-licensing of our Guardian Technology pipeline product candidates.”
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.